The biosimilars reach the US market as the US insulin space has seen seismic changes in the last few years, with a clamour of ...

LixiLan is a fixed-ratio combination of basal insulin glargine 100 units/ml – marketed on its own as Lantus - matched with the GLP-1 receptor agonist lixisenatide, the active ingredient in ...

GLP-1 medications initially were used to help people with diabetes improve their insulin resistance and hunger cravings.

to 182.5 ± 21.6 (GLP-1) and 194.8 ± 19.5 (combination) (P < 0.001). Fasting insulin levels were not significantly different between the groups (58 ± 15 [saline], 89 ± 27 [GLP-1], 53 ± 13 ...

The two incretin hormones, glucagon-like peptide (GLP)-1 and glucose-dependent insulinotropic polypeptide potentiate nutrient-dependent insulin secretion following meal ingestion. Metabolic ...

today announced its intention to initiate a clinical study on the combination of the Allurion Program with GLP-1 agonists to improve muscle mass and overall body composition. Previous studies in ...

The FDA has approved the first rapid-acting biosimilar insulin product for glycemic control ... Among patients with type 2 diabetes, use of GLP-1 agonists may increase the risks for adhesive ...

Soliqua is a once-daily injectable combination drug containing insulin, glargine 100 units/ml, which is a long-acting basal insulin and lixisenatide, a GLP-1 receptor agonist. India Has The 2nd ...

in combination with a GLP-1 receptor agonist (i.e., semaglutide) to assess key metabolic parameters in animal models including: improvements in C-peptide index, a marker of insulin secretion and ...